{"id":72166,"date":"2026-08-10T13:10:26","date_gmt":"2026-08-10T05:10:26","guid":{"rendered":"https:\/\/flcube.com\/?p=72166"},"modified":"2026-08-10T13:10:27","modified_gmt":"2026-08-10T05:10:27","slug":"braveheart-bio-hengrui-pharma-partner-debuts-on-nasdaq-with-usd-439-9-million-ipo-powered-by-hrs-1893-cardiac-myosin-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72166","title":{"rendered":"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Braveheart Bio<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/BRVE:NASDAQ\">NASDAQ: <strong>BRVE<\/strong><\/a>), a partner of <strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1276:HKG\">HKG: 1276<\/a>), began trading on the <strong>NASDAQ Stock Exchange<\/strong> in the United States. The offering generated total gross proceeds of approximately <strong>USD 439.9 million<\/strong> (before deducting underwriting discounts, commissions, and offering expenses payable by Braveheart Bio), including the <strong>full exercise of the underwriters&#8217; over\u2011allotment option<\/strong> to purchase additional shares.<\/p>\n\n\n\n<h2 id=\"h-ipo-milestone\" class=\"wp-block-heading\">IPO Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Braveheart Bio (NASDAQ: BRVE)<\/td><\/tr><tr><td><strong>Exchange<\/strong><\/td><td>NASDAQ Stock Exchange (US)<\/td><\/tr><tr><td><strong>Listing Date<\/strong><\/td><td>6 Aug 2026<\/td><\/tr><tr><td><strong>Gross Proceeds<\/strong><\/td><td>\u2248 USD 439.9 million (pre\u2011expenses)<\/td><\/tr><tr><td><strong>Over\u2011Allotment<\/strong><\/td><td>Fully exercised by underwriters<\/td><\/tr><tr><td><strong>Strategic Partner<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals (SHA: 600276; HKG: 1276)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-core-asset\" class=\"wp-block-heading\">Company Profile &amp; Core Asset<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2024 \u2014 focused on developing novel therapies for <strong>hypertrophic cardiomyopathy (HCM)<\/strong> and other serious cardiovascular diseases.<\/li>\n\n\n\n<li><strong>Core Asset:<\/strong> <strong>HRS\u20111893<\/strong> (known as <strong>BHB\u20111893<\/strong> outside Greater China), a <strong>next\u2011generation small\u2011molecule cardiac myosin inhibitor<\/strong> independently developed by <strong>Hengrui Pharma<\/strong>.<\/li>\n\n\n\n<li><strong>Clinical Status:<\/strong> Under clinical development primarily for <strong>obstructive HCM (oHCM)<\/strong> and <strong>non\u2011obstructive HCM (nHCM)<\/strong>.<\/li>\n\n\n\n<li><strong>Positioning:<\/strong> The asset underpins Braveheart Bio&#8217;s entry into the capital market, giving the newly listed company a differentiated cardiovascular pipeline anchored by an established pharma R&amp;D engine.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-licensing-agreement-with-hengrui-pharma-september-2025\" class=\"wp-block-heading\">Licensing Agreement With Hengrui Pharma (September 2025)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Term<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Scope<\/strong><\/td><td>Exclusive global rights (ex\u2011Mainland China, Hong Kong SAR, Macau SAR, and Taiwan region) to develop, manufacture, and commercialize HRS\u20111893<\/td><\/tr><tr><td><strong>Upfront Cash<\/strong><\/td><td>USD 32.5 million<\/td><\/tr><tr><td><strong>Equity Component<\/strong><\/td><td>32.5 million shares of Braveheart Bio non\u2011voting Class A preferred stock (USD 1.00 per share)<\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>Up to USD 23 million (technology transfer and development)<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>Up to USD 1 billion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Alliance:<\/strong> The Hengrui\u2013Braveheart structure pairs one of China&#8217;s largest pharmaceutical companies with a US\u2011listed biotech, a model increasingly used to globalize late\u2011stage Chinese assets.<\/li>\n\n\n\n<li><strong>HCM Focus:<\/strong> Hypertrophic cardiomyopathy remains an area with substantial unmet medical need, and cardiac myosin inhibitors represent a targeted mechanistic approach attracting investor attention in cardiovascular drug development.<\/li>\n\n\n\n<li><strong>Capital Position:<\/strong> The fully subscribed over\u2011allotment and nearly USD 440 million in gross proceeds provide Braveheart Bio with resources to advance the BHB\u20111893 clinical program.<\/li>\n\n\n\n<li><strong>Milestone Alignment:<\/strong> Hengrui Pharma&#8217;s exposure \u2014 upfront cash, preferred equity, and up to USD 1.023 billion in combined milestones \u2014 aligns both parties&#8217; incentives around clinical and commercial success.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Braveheart Bio&#8217;s capital markets activities and the clinical development and commercialization of HRS\u20111893\/BHB\u20111893. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[30,4336,2586,4228,72,852],"class_list":["post-72166","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-braveheart-bio","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-ipo","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276), began trading on the NASDAQ Stock Exchange in the United States. The offering generated total gross proceeds of approximately USD 439.9 million (before deducting underwriting discounts, commissions, and offering expenses payable by Braveheart Bio), including the full exercise of the underwriters&#039; over\u2011allotment option to purchase additional shares.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72166\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor\" \/>\n<meta property=\"og:description\" content=\"Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276), began trading on the NASDAQ Stock Exchange in the United States. The offering generated total gross proceeds of approximately USD 439.9 million (before deducting underwriting discounts, commissions, and offering expenses payable by Braveheart Bio), including the full exercise of the underwriters&#039; over\u2011allotment option to purchase additional shares.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72166\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T05:10:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T05:10:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72166#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72166\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor\",\"datePublished\":\"2026-08-10T05:10:26+00:00\",\"dateModified\":\"2026-08-10T05:10:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72166\"},\"wordCount\":425,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Braveheart Bio\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"IPO\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72166#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72166\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72166\",\"name\":\"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-10T05:10:26+00:00\",\"dateModified\":\"2026-08-10T05:10:27+00:00\",\"description\":\"Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276), began trading on the NASDAQ Stock Exchange in the United States. The offering generated total gross proceeds of approximately USD 439.9 million (before deducting underwriting discounts, commissions, and offering expenses payable by Braveheart Bio), including the full exercise of the underwriters' over\u2011allotment option to purchase additional shares.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72166#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72166\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72166#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276), began trading on the NASDAQ Stock Exchange in the United States. The offering generated total gross proceeds of approximately USD 439.9 million (before deducting underwriting discounts, commissions, and offering expenses payable by Braveheart Bio), including the full exercise of the underwriters' over\u2011allotment option to purchase additional shares.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72166","og_locale":"en_US","og_type":"article","og_title":"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor","og_description":"Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276), began trading on the NASDAQ Stock Exchange in the United States. The offering generated total gross proceeds of approximately USD 439.9 million (before deducting underwriting discounts, commissions, and offering expenses payable by Braveheart Bio), including the full exercise of the underwriters' over\u2011allotment option to purchase additional shares.","og_url":"https:\/\/flcube.com\/?p=72166","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T05:10:26+00:00","article_modified_time":"2026-08-10T05:10:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72166#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72166"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor","datePublished":"2026-08-10T05:10:26+00:00","dateModified":"2026-08-10T05:10:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72166"},"wordCount":425,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Braveheart Bio","Hengrui Pharmaceuticals","HKG: 1276","IPO","SHA: 600276"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72166#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72166","url":"https:\/\/flcube.com\/?p=72166","name":"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-10T05:10:26+00:00","dateModified":"2026-08-10T05:10:27+00:00","description":"Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276), began trading on the NASDAQ Stock Exchange in the United States. The offering generated total gross proceeds of approximately USD 439.9 million (before deducting underwriting discounts, commissions, and offering expenses payable by Braveheart Bio), including the full exercise of the underwriters' over\u2011allotment option to purchase additional shares.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72166#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72166"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72166#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS\u20111893 Cardiac Myosin Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72166"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72166\/revisions"}],"predecessor-version":[{"id":72168,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72166\/revisions\/72168"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}